Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 2 2Phase 1/2 1

Status

Completed 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Ovarian Neoplasms 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × mirvetuximab soravtansine × Clear all
NCT04209855 2025-08-27

MIRASOL

AbbVie

Phase 3 Completed
453 enrolled 18 charts 1 FDA
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04296890 2024-08-07

SORAYA

ImmunoGen, Inc.

Phase 3 Completed
106 enrolled 14 charts 1 FDA
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02631876 2020-10-14

FORWARD I

ImmunoGen, Inc.

Phase 3 Completed
366 enrolled 20 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡